X

Leveraging academic medicine into innovative therapies through partnerships

Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development

Clinical Trials

Vamorolone is in clinical testing for DMD, with 46 patients enrolled in VBP15-LTE (NCT03038399) and recruitment of 120 new patients initiated for VBP15-004 (NCT03439670).
Learn more >

About vamorolone

Vamorolone Phase 2a study complete.

Phase 2b study initiated.

Learn More

Research

microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.

Learn More

News

Rockville, MD –  22 August 2018
ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy. More >

Learn More